# AGR2 curation notes

AGR2 is a secretory-pathway/ER-retained anterior gradient protein with a thioredoxin-like fold and a conserved C-terminal KTEL retrieval motif. The strongest physiological evidence supports a role in mucin-producing epithelial cells rather than a general extracellular cancer signaling role. In mouse intestine, AGR2 is present in the ER of secretory epithelial cells and is required for in vivo MUC2 production; the active-site cysteine forms mixed disulfide bonds with MUC2, indicating a direct role in mucin processing [PMID:19359471 "Here, we show that AGR2 is present within the ER of intestinal secretory epithelial cells and is essential for in vivo production of the intestinal mucin MUC2"; PMID:19359471 "A cysteine residue within the AGR2 thioredoxin-like domain forms mixed disulfide bonds with MUC2"].

Human genetics supports the same core function. Siblings with biallelic AGR2 H117Y had reduced goblet cells, depletion of MUC2/MUC5AC/MUC6, increased ER stress, and infantile IBD; mutant AGR2 bound MUC2 less well and was less able to alleviate tunicamycin-induced ER stress [PMID:34237462 "Patient biopsy specimens showed reduced goblet cells; depletion of MUC2, MUC5AC, and MUC6; up-regulation of AGR2; and increased ER stress"; PMID:34237462 "The mutant AGR2 showed reduced capacity to bind MUC2 and alleviate tunicamycin-induced ER stress"].

PN re-review 2026-06-03: Falcon deep research is already present for AGR2, and the Proteostasis projection source maps AGR2 only from ER proteostasis|Folding enzyme|Protein disulfide isomerases to GO:0003756 protein disulfide isomerase activity. I accept that projection after gene-level review because AGR2 has direct AGR2-MUC2 mixed-disulfide evidence and human AGR2 H117Y reduces MUC2 binding/ER-stress relief [PMID:19359471 "A cysteine residue within the AGR2 thioredoxin-like domain forms mixed disulfide bonds with MUC2"; PMID:34237462 "The mutant AGR2 showed reduced capacity to bind MUC2 and alleviate tunicamycin-induced ER stress"]. I do not extend the PN projection to broad ER proteostasis or generic positive UPR terms. The newer IRE1beta work supports a separate, narrow negative IRE1-mediated UPR annotation in mucin-producing/goblet-cell contexts [PMID:38177501 "AGR2 binding to IRE1β disrupts IRE1β oligomerization, thereby blocking its downstream endonuclease activity"; PMID:38177498 "The mucin-specific chaperone AGR2 repressed IRE1 activity in cells expressing the domain-swapped IRE1β/α chimera, but had no effect on IRE1α"].

AGR2 ER residence is functionally important: deleting the KTEL motif causes secretion and loss of the AREG/CDX2 readouts, and KDEL/KSEL substitutions retain ER residence but do not rescue function [PMID:22184114 "Deletion of the KTEL motif results in AGR2 secretion and loss of AGR2 function"]. This argues that wild-type AGR2's core site of action is the ER lumen, even though extracellular AGR2 can be detected and has context-dependent activities.

AGR2 dimerization is a major regulatory feature. Structural and biochemical studies show monomer-dimer equilibrium [PMID:23274113 "The protein exists in monomer-dimer equilibrium with a K(d) of 8.83μM"], and AGR2 dimers are proposed to act as sensors of ER homeostasis; perturbation can drive secretion of monomers and pro-inflammatory monocyte chemoattraction [PMID:31040128 "AGR2 dimers act as sensors of ER homeostasis which are disrupted upon ER stress and promote the secretion of AGR2 monomers"; PMID:31040128 "the extracellular release of AGR2 leads to the chemoattraction of monocytes"].

Non-core/contextual annotations: AGR2 binds EGFR in the ER and controls EGFR delivery/signaling in cancer-cell models [PMID:25666625 "EGFR binding to anterior gradient homolog 2 ( AGR2 ) in the endoplasmic reticulum is required for receptor delivery to the plasma membrane and thus EGFR signaling"]. AGR2 also has yeast-two-hybrid evidence for binding C4.4a/LYPD3 and alpha-dystroglycan, but the original paper cautioned that clinical confirmation was needed [PMID:12592373 "Yeast two-hybrid cloning identified metastasis-associated GPI-anchored C4.4a protein and extracellular alpha-dystroglycan (DAG-1) as binding partners"; PMID:12592373 "Clearly, further analyses such as coimmunoprecipitation are required to confirm that these interactions occur in clinical cancers"].

Literature conflict to track: the EGFR study argued that EGFR is a major AGR2 substrate and explicitly reported that MUC2 was not detected in their AGR2 mixed-disulfide mass-spectrometry analysis, citing a re-evaluation that MUC2 was not an AGR2-binding protein and that AGR2 had no role in MUC2 folding [PMID:25666625 "Re-evaluation of MUC2 in a recent study also concluded that it is not a AGR2-binding protein and that AGR2 served no role in its folding"]. I still weight the MUC2/mucin-processing model as core because PMID:19359471 directly trapped AGR2-MUC2 mixed disulfides and the later human deficiency paper showed that AGR2 H117Y has reduced MUC2 binding and reduced capacity to alleviate tunicamycin-induced ER stress [PMID:34237462 "The mutant AGR2 showed reduced capacity to bind MUC2 and alleviate tunicamycin-induced ER stress"].